Mefloquine sensitizes chronic myeloid leukemia (CML) cells derived from patients in chronic phase to TK inhibitors showing selectivity for stem/progenitor tumoral cells to normal cells [141]. Here, TKT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.